The potential role of CUR in regorafenib (RG)-treated KRAS mutant CRC cancer is indicated by the fact that CUR may target one additional gene other than mutant KRAS [100] (Table 1, Figure 1). This evidence concerns the gene KRAS and colorectal carcinoma.